A study led by McMaster University researchers shows that a widely available and inexpensive medication not only prevents ...

The drug is predicted to have the potential to save some $4,950 per patient on average, according to a new study.

This is a randomized controlled study conducted at the NCI from December 2021 to September 2022, including children and adolescents age between 3 and 18 years who presented to the emergency room with ...

A new analysis from the Institute for Clinical and Economic Review has found that blockbuster GLP-1 drugs from Novo Nordisk and Eli Lilly offer substantial health benefits and are a cost-effective ...

CKD screening at age 55, combined with SGLT2 inhibitors, reduces kidney failure incidence and improves life expectancy across racial and ethnic groups. Non-Hispanic Black adults experience the most ...

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial We derived disease progression and therapy ...

(Reuters) - An influential drug pricing watchdog on Tuesday said popular GLP-1 weight-loss injections have become more cost-effective as their prices have fallen and studies have shown proof of their ...

ICER rates semaglutide and tirzepatide as cost effective vs lifestyle modifications Lilly's tirzepatide shows "promising but inconclusive" cost-effectiveness vs Novo's semaglutide Net prices of both ...